S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
Log in

NASDAQ:ABMDABIOMED Stock Price, Forecast & News

$150.05
+8.65 (+6.12 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$143.43
Now: $150.05
$150.78
50-Day Range
$130.51
MA: $151.92
$169.00
52-Week Range
$119.01
Now: $150.05
$288.09
Volume52,573 shs
Average Volume838,405 shs
Market Capitalization$6.76 billion
P/E Ratio28.20
Dividend YieldN/A
Beta0.61
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More
ABIOMED logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$769.43 million
Cash Flow$4.24 per share
Book Value$20.78 per share

Profitability

Net Income$259.02 million

Miscellaneous

Employees1,371
Market Cap$6.76 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.


ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

How has ABIOMED's stock been impacted by COVID-19 (Coronavirus)?

ABIOMED's stock was trading at $151.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABMD stock has decreased by 0.7% and is now trading at $150.05. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ABIOMED?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ABIOMED.

When is ABIOMED's next earnings date?

ABIOMED is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for ABIOMED.

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, February, 6th. The medical equipment provider reported $1.51 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.09 by $0.42. The medical equipment provider had revenue of $221.60 million for the quarter, compared to analysts' expectations of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the business posted $0.97 EPS. View ABIOMED's earnings history.

What guidance has ABIOMED issued on next quarter's earnings?

ABIOMED updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $846-877 million, compared to the consensus revenue estimate of $885.43 million.

What price target have analysts set for ABMD?

9 equities research analysts have issued 12 month price targets for ABIOMED's stock. Their forecasts range from $149.00 to $340.00. On average, they anticipate ABIOMED's share price to reach $224.80 in the next year. This suggests a possible upside of 49.8% from the stock's current price. View analysts' price targets for ABIOMED.

What are Wall Street analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:
  • 1. According to Zacks Investment Research, "ABIOMED wrapped up fourth-quarter fiscal 2019 on a mixed note. Competition in the MedTech industry is intense. Pricing pressure and foreign currency headwinds persist. ABIOMED has underperformed the industry in a year’s time. However, the company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoption are added positives. Revenues from Japan also skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. In fact, the company continues to invest in training and education. The recent CE Mark of the Impella Connect is encouraging as well. The company’s balance sheet is debt-free." (5/8/2019)
  • 2. BTIG Research analysts commented, "Term; Trimming PT to $340 From $400 Abiomed missed estimates in the quarter, delivering sales of $207M, short of consensus’ $219M forecast. Most of the weakness was U.S. driven, due to a weak cath lab (also seen in peer results) and to a greater extent, mix disruption leading to mgmt’s disproportionate focus away from protected PCI/elective procedures. To reflect these pressures, mgmt’s initial FY20 outlook calls for revenue growth of 17-23%, 6% below what mgmt (and we) would’ve considered more likely (and exactly the exact magnitude of the FQ4 shortfall). Mgmt outlined a number of initiatives to address these issues and noted that April is reportedly promising. The fact that mgmt still remains confident in addressable market and has left room to revise guidance during its next earnings call suggest there is good chance of upside." (5/7/2019)

Has ABIOMED been receiving favorable news coverage?

News articles about ABMD stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABIOMED earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutABIOMED.

Who are some of ABIOMED's key competitors?

What other stocks do shareholders of ABIOMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ABIOMED investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Arista Networks (ANET), Align Technology (ALGN), Netflix (NFLX), Square (SQ), bluebird bio (BLUE), salesforce.com (CRM) and Paypal (PYPL).

Who are ABIOMED's key executives?

ABIOMED's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
  • Dr. David M. Weber, Chief Operating Officer (Age 58)
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
  • Mr. William J. Bolt, Exec. Officer (Age 67)
  • Mr. Ian McLeod, VP & Corp. Controller

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How do I buy shares of ABIOMED?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABMD stock can currently be purchased for approximately $150.05.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $6.76 billion and generates $769.43 million in revenue each year. The medical equipment provider earns $259.02 million in net income (profit) each year or $3.60 on an earnings per share basis. ABIOMED employs 1,371 workers across the globe. View additional information about ABIOMED.

What is ABIOMED's official website?

The official website for ABIOMED is http://www.abiomed.com/.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Featured Article: Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel